Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 +1.01%12 Days Payable is 59.78 as of Mar. 2026, which is 51% below its 10-year median of 122.03. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 926 Drug Manufacturers companies, Astonea Labs ranks better than 86.83% on this metric.
The historical rank and industry rank for Astonea Labs's Days Payable or its related term are showing as below:
BOM:544409'
s Days Payable Range Over the Past 10 Years
Min: 105.93 Med: 122.03 Max: 249.25
Current: 223.5
During the past 5 years, Astonea Labs's highest Days Payable was 249.25. The lowest was 105.93. And the median was 122.03.
BOM:544409's Days Payable is ranked better than 86.83% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs BOM:544409: 223.50
Astonea Labs's Days Payable
increased
from Mar. 2024 (0.00) to Mar. 2026 (59.78).
It may suggest that Astonea Labsdelayed paying its suppliers.
Astonea Labs Days Payable Related Terms
Astonea Labs Days Payable Historical Data
* Premium members only.
The historical data trend for Astonea Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where Astonea Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Astonea Labs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astonea Labs (BOM:544409) has a Days Payable of 59.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Astonea Labs and its competitors. This is 51% below median its historical median of 122.03. Over the past decade, Astonea Labs' Days Payable has ranged from 105.93 to 249.25. According to the industry distribution chart, Astonea Labs ranks #122 out of 926 companies in the Drug Manufacturers industry, placing it in the top 13.2%.
Is Astonea Labs' Days Payable too high?
Astonea Labs' current Days Payable of 59.78 is 51% below median its 10-year median of 122.03. Over the past 10 years, this metric has ranged from a low of 105.93 to a high of 249.25. The Drug Manufacturers industry median Days Payable is 90.22. Astonea Labs' value of 59.78 is 33.7% below this industry median. Based on the distribution chart, Astonea Labs ranks #122 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #122 out of 926 companies for Days Payable. This places Astonea Labs in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.22. Astonea Labs' value of 59.78 is 33.7% below this benchmark. Historically, Astonea Labs' own Days Payable has ranged from 105.93 to 249.25 over the past decade. While the company's 10-year median is 122.03 vs. the industry median of 90.22, Astonea Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astonea Labs's current Days Payable of 59.78 is 33.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current Days Payable is 59.78, which is 51% below median its own 10-year median of 122.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current Days Payable of 59.78. The current Days Payable is 59.78, which is 51% below median its 10-year median of 122.03 and 33.7% below the Drug Manufacturers industry median of 90.22. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current Days Payable is 59.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
